Patents by Inventor David A. Bumcrot

David A. Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)
    Publication number: 20150252358
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 10, 2015
    Inventors: Morgan L. Maeder, David A. Bumcrot, Shen Shen
  • Compositions and methods for inhibiting expression of Eg5 gene
    Patent number: 9057069
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 16, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Compositions and methods for inhibiting expression of Eg5 and VEGF genes
    Patent number: 9006197
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: April 14, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska
  • GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
    Publication number: 20150099794
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 8889644
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 18, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Greg Hinkle, Ivanka Toudjarska, David Bumcrot
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes
    Publication number: 20140336243
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 13, 2014
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska, Jared Gollob, Akshay Vaishnaw, Christina Gamba-Vitalo
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20140309411
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: May 20, 2014
    Publication date: October 16, 2014
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
    Patent number: 8859516
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 14, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska, Jared Gollob, Akshay Vaishnaw, Christina Gamba-Vitalo
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Eg5 And VEGF Genes
    Publication number: 20140288154
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a lipid formulation, and methods of using the compositions to inhibit the expression of the Human kinesin family member 11 (Eg5) and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Akin Akinc, Dinah Wen-Yee Sah, Tatiana Novobrantseva
  • ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
    Publication number: 20140275211
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: June 21, 2012
    Publication date: September 18, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Dinah Sah, David Bumcrot, Alfica Sehgal
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20140235693
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal. In one embodiment, an iRNA for inhibiting expression of a Serpinal gene includes at least two sequences that are complementary to each other. The iRNA includes a sense strand having a first sequence and an antisense strand having a second sequence. The antisense strand includes a nucleotide sequence that is substantially complementary to at least part of an mRNA encoding Serpinal, and the region of complementarity is 30 nucleotides or less, and at least 15 nucleotides in length. Generally, the iRNA is 19 to 24, e.g., 19 to 21 nucleotides in length.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 21, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Therapeutic compositions
    Patent number: 8809516
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: August 19, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • RNA interference modulators of hedgehog signaling and uses thereof
    Patent number: 8802639
    Abstract: The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: August 12, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventor: David A. Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20140194489
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: March 28, 2012
    Publication date: July 10, 2014
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • Therapeutic compositions
    Patent number: 8754201
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: June 17, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE
    Publication number: 20130274311
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 17, 2013
    Inventors: David Bumcrot, Pamela Tan, Hans-Peter Vornlocher, Anke Geick
  • Therapeutic compositions
    Patent number: 8445665
    Abstract: This application relates to iRNA agents and methods of making and using the agents. The iRNA agent comprises a sense sequence and an antisense sequence. The antisense strand and/or the sense strand may contain formula (8) or its L-nucleoside or 2?-5? linkage isomer: The iRNA agents of the invention can present increased nuclease resistance.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 21, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
    Publication number: 20130023577
    Abstract: This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, and methods of using the compositions to inhibit the expression of the Eg5 and Vascular Endothelial Growth Factor (VEGF), and methods of using the compositions to treat pathological processes mediated by Eg5 and VEGF expression, such as cancer.
    Type: Application
    Filed: April 9, 2012
    Publication date: January 24, 2013
    Inventors: David Bumcrot, Dinah Wen-Yee Sah, Ivanka Toudjarska
  • GNAQ TARGETED dsRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION
    Publication number: 20130012570
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Inventors: Jared Gollob, Greg Hinkle, Ivanka Toudjarska, David Bumcrot
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 8324368
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: December 4, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot